What is the difference between Seladelpar and Befentinol?

Seladelpar () and befentinol (Bepirovirsen) are two drugs with different mechanisms of action and indications, and are used to treat different types of diseases.

First of all, Siladepa is a selective PPARdelta receptor agonist, mainly used to treat cholestatic liver diseases such as primary biliary cholangitis (PBC). It improves liver inflammation and fibrosis by regulating lipid metabolism and anti-inflammatory effects, alleviates the condition, and promotes liver function recovery. Siladepa is administered in oral form, and studies have shown that its safety and efficacy are relatively satisfactory, making it an emerging treatment option in the field of liver diseases.

Befentinol is an antisense oligonucleotide drug targeting the core protein of hepatitis B virus (HBV) and belongs to the field of nucleic acid therapy. It suppresses the virus and improves immune response by inhibiting the expression of viral core proteins, reducing viral replication and antigen production. Befentinol is primarily used in patients with chronic hepatitis B, especially those who have failed to respond to existing antiviral treatments.

The main difference between the two is the indications and mechanism of action: Siladepa focuses on the treatment of immune-mediated liver inflammatory diseases and is a metabolic regulator; befentinol directly targets viral gene expression and is an antiviral nucleic acid drug. In addition, the administration methods are also different. Siladepa is an oral small molecule drug, while befentinol is administered by injection. Overall, these two drugs represent different directions in metabolic regulation and gene therapy in the field of liver disease treatment.

Reference materials:https://www.drugs.com/